Recursion Pharmaceuticals (NASDAQ:RXRX) Director Blake Borgeson Sells 220,000 Shares

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Director Blake Borgeson sold 220,000 shares of the stock in a transaction dated Tuesday, January 6th. The stock was sold at an average price of $4.36, for a total transaction of $959,200.00. Following the sale, the director owned 6,649,863 shares of the company’s stock, valued at $28,993,402.68. This trade represents a 3.20% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

Blake Borgeson also recently made the following trade(s):

• On Tuesday, December 2nd, Blake Borgeson sold 220,000 shares of Recursion Pharmaceuticals stock. The shares were sold at an average price of $4.37, for a total transaction of $961,400.00.

Recursion Pharmaceuticals Price Performance

Recursion Pharmaceuticals stock traded down $0.16 during midday trading on Thursday, reaching $4.70. The company’s stock had a trading volume of 17,070,189 shares, compared to its average volume of 21,434,861. The stock’s 50 day simple moving average is $4.50 and its 200 day simple moving average is $5.07. Recursion Pharmaceuticals, Inc. has a fifty-two week low of $3.79 and a fifty-two week high of $12.36. The company has a debt-to-equity ratio of 0.01, a quick ratio of 4.60 and a current ratio of 4.60. The firm has a market capitalization of $2.44 billion, a PE ratio of -2.61 and a beta of 0.95.

Recursion Pharmaceuticals (NASDAQ:RXRX) last released its quarterly earnings data on Wednesday, November 5th. The company reported ($0.36) EPS for the quarter, topping the consensus estimate of ($0.38) by $0.02. The business had revenue of $5.18 million for the quarter, compared to analyst estimates of $19.36 million. Recursion Pharmaceuticals had a negative net margin of 1,637.81% and a negative return on equity of 72.74%. The business’s revenue for the quarter was down 80.1% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.34) EPS. On average, equities research analysts forecast that Recursion Pharmaceuticals, Inc. will post -1.57 earnings per share for the current year.

Institutional Trading of Recursion Pharmaceuticals

Several hedge funds and other institutional investors have recently bought and sold shares of RXRX. Brighton Jones LLC raised its position in Recursion Pharmaceuticals by 49.4% in the fourth quarter. Brighton Jones LLC now owns 20,261 shares of the company’s stock worth $137,000 after purchasing an additional 6,699 shares in the last quarter. Royal Bank of Canada boosted its holdings in Recursion Pharmaceuticals by 627.6% during the first quarter. Royal Bank of Canada now owns 269,013 shares of the company’s stock worth $1,423,000 after buying an additional 232,038 shares during the last quarter. Advisors Asset Management Inc. increased its position in shares of Recursion Pharmaceuticals by 753.8% in the 1st quarter. Advisors Asset Management Inc. now owns 133,485 shares of the company’s stock valued at $706,000 after buying an additional 117,851 shares in the last quarter. AQR Capital Management LLC bought a new position in Recursion Pharmaceuticals in the first quarter valued at approximately $890,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in shares of Recursion Pharmaceuticals by 7.5% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 177,434 shares of the company’s stock worth $953,000 after buying an additional 12,372 shares in the last quarter. 89.06% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on the stock. Morgan Stanley set a $11.00 target price on shares of Recursion Pharmaceuticals in a research report on Wednesday, December 17th. Needham & Company LLC reiterated a “buy” rating and issued a $8.00 price objective on shares of Recursion Pharmaceuticals in a research report on Thursday, September 11th. JPMorgan Chase & Co. raised Recursion Pharmaceuticals from a “neutral” rating to an “overweight” rating and increased their price target for the stock from $10.00 to $11.00 in a research note on Wednesday, December 17th. UBS Group set a $11.00 price objective on shares of Recursion Pharmaceuticals in a research note on Wednesday, December 17th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a research report on Wednesday, October 8th. Two analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $9.40.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc (NASDAQ: RXRX) is a biopharmaceutical company that combines advanced automation, artificial intelligence and high-throughput biology to discover and develop novel therapeutics. The company’s proprietary platform integrates deep-learning algorithms with large-scale cellular imaging and chemical biology, enabling the rapid identification of potential drug candidates across a range of indications. By automating complex laboratory workflows and leveraging computational models, Recursion aims to accelerate the drug discovery process and expand the scope of targets that can be addressed.

At the core of Recursion’s offering is its digital biology platform, which captures billions of cell images under varying chemical and genetic perturbations.